Alzheimer's Disease (AD) Clinical Trials


A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Condition:   Alzheimer´s Disease
Interventions:   Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg;   Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg;   Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg;   Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
Sponsors:   Baxalta US Inc.;   Alzheimer's Disease Cooperative Study (ADCS)
Completed - verified October 2014

Learn More

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Condition:   Alzheimer's Disease
Interventions:   Biological: PF-04360365 0.1 mg/kg;   Biological: PF-04360365 0.5 mg/kg;   Biological: PF-04360365 1 mg/kg;   Drug: Placebo;   Biological: PF-04360365 3 mg/kg;   Biological: PF-04360365 8.5 mg/kg
Sponsor:   Pfizer
Completed - verified October 2012

Learn More

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

Condition:   Alzheimer's Disease
Interventions:   Drug: Dimebon;   Drug: Dimebon;   Drug: Placebo
Sponsor:   Medivation, Inc.
Completed - verified September 2016

Learn More

Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

Condition:   Alzheimer's Disease
Intervention:   Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
Sponsor:   University Hospital, Strasbourg, France
Withdrawn - verified November 2012

Learn More

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Condition:   Alzheimer Disease
Intervention:   Drug: galantamine
Sponsor:   Janssen Pharmaceutical K.K.
Completed - verified January 2011

Learn More

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Condition:   Alzheimer's Disease
Interventions:   Drug: Crenezumab;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified June 2017

Learn More

A Study of MP-101 in the Treatment of Psychosis in Alzheimer's Disease

Conditions:   Psychosis;   Alzheimer Disease
Interventions:   Drug: MP-101;   Drug: Placebo
Sponsor:   Mediti Pharma Inc.
Recruiting - verified July 2017

Learn More

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Conditions:   Alzheimer's Disease;   Dementia With Lewy Bodies;   Parkinson's Disease Dementia
Interventions:   Drug: RVT-101 35 mg;   Drug: Placebo
Sponsor:   Axovant Sciences Ltd.
Recruiting - verified June 2017

Learn More

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

Conditions:   Alzheimer Disease;   Cognition Disorders
Intervention:   Drug: florbetapir F 18 PET scan
Sponsors:   Avid Radiopharmaceuticals;   Eli Lilly and Company;   PRA Health Sciences
Recruiting - verified July 2017

Learn More

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Conditions:   Mild Cognitive Impairment (MCI);   Alzheimer's Disease (AD)
Intervention:  
Sponsors:   University of Southern California;   Northern California Institute of Research and Education;   National Institute on Aging (NIA);   Alzheimer's Therapeutic Research Institute
Recruiting - verified July 2017

Learn More

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

Condition:   Alzheimer's Disease
Intervention:   Drug: 18F-AV-1451
Sponsor:   Avid Radiopharmaceuticals
Recruiting - verified July 2017

Learn More

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Condition:   Alzheimer's Disease
Interventions:   Drug: LY3202626;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified July 2017

Learn More

Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial

Conditions:   Mild Cognitive Impairment;   Dementia;   Alzheimer's Disease
Intervention:  
Sponsor:   University of Utah
Recruiting - verified July 2017

Learn More

Implications for Management of PET Amyloid Classification Technology

Conditions:   Mild Cognitive Impairment;   Dementia;   Alzheimer's Disease
Intervention:   Drug: [18F]Flutemetamol
Sponsor:   University of Utah
Recruiting - verified July 2017

Learn More

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Condition:   Alzheimer's Disease
Interventions:   Drug: LY3303560 - IV;   Drug: Saline Solution - IV;   Drug: LY3303560 - SC
Sponsor:   Eli Lilly and Company
Recruiting - verified July 2017

Learn More

16-30 of 48
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.